AstraZeneca to discontinue rare blood cancer drug in the US
AstraZeneca is retiring Lumoxiti, its third-line treatment for a rare type of blood cancer called hairy cell leukemia (HCL), the company confirmed to Endpoints News on Thursday.
The drug will be permanently discontinued in the US as of July 2023, in part due to competition from rivals, a spokesperson said in an email. The decision “does not reflect any new concerns about the safety or efficacy” of Lumoxiti, but rather “an evaluation of the utilization” of the drug and “the availability of other treatments that are more widely prescribed.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.